Esperion Therapeutics Income Statement - Quarterly (NASDAQ:ESPR)

Add to My Stocks
$36.69 $0.69 (1.85%) ESPR stock closing price Apr 21, 2017 (Closing)

ESPR stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Esperion Therapeutics stock price. The income statement is a summary of the revenue, expenses and profitability (shown as Net Income) or lack of it. The income statement is generated for a specific period of time. Investors typically check year over year or quarter over quarter revenue growth. The operating expenses (also check: Esperion Therapeutics assets and Esperion Therapeutics free cash flow) as shown in the Esperion Therapeutics profit and loss statement 2016-Q4 total to $29.3M. This line item has increased from $17.7M compared with last quarter. View details of revenue and profits for Esperion Therapeutics for latest & last 40 quarters.

show more
Annual
Quarterly
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Esperion Therapeutics Net Sales or Revenues
----------
Cost Of Goods Sold (COGS)----------
Esperion Therapeutics Gross Profit
----------
Research & Development Expense24.89M13.49M9.69M9.79M7.97M7.24M7.2M7.39M6.21M7.17M
Selling General & Admin Expense4.41M4.21M4.63M5.03M5.28M5.67M5.25M4.03M3.19M2.52M
Income Before Depreciation Depletion Amortization-29.29M-17.71M-14.33M-14.82M-13.25M-12.91M-12.46M-11.42M-9.38M-9.7M
Depreciation Depletion Amortization----------
Non Operating Income0.42M0.39M0.39M0.34M0.24M0.24M0.2M0.09M0.07M0.02M
Interest Expense0.09M0.08M0.09M0.11M0.13M0.13M0.13M0.13M0.14M0.13M
Esperion Therapeutics Pretax Income
-28.96M-17.4M-14.03M-14.58M-13.13M-12.8M-12.39M-11.46M-9.47M-9.8M
Provision for Income Taxes----------
Minority Interest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-28.96M-17.4M-14.04M-14.59M-13.12M-12.8M-12.4M-11.47M-9.46M-9.81M
Extraordinary Items & Discontinued Operations----------
Esperion Therapeutics Net Income (Profit/Loss)
-28.96M-17.4M-14.04M-14.59M-13.12M-12.8M-12.4M-11.47M-9.46M-9.81M
Average Shares used to compute Diluted EPS22.55M22.55M22.54M22.53M22.52M22.49M22.47M20.59M19.28M15.43M
Average Shares used to compute Basic EPS22.55M22.55M22.54M22.53M22.52M22.49M22.47M20.59M19.28M15.43M
Income Before Nonrecurring Items-28.96M-17.4M-14.04M-14.59M-13.12M-12.8M-12.4M-11.47M-9.46M-9.81M
Income from Nonrecurring Items----------
Esperion Therapeutics Earnings Per Share Basic Net
-1.29-0.77-0.62-0.65-0.58-0.57-0.55-0.56-0.49-0.64
Esperion Therapeutics Earnings Per Share Diluted Net
-1.29-0.77-0.62-0.65-0.58-0.57-0.55-0.56-0.49-0.64
EPS Diluted Before Nonrecurring Items-1.29-0.77-0.62-0.65-0.58-0.57-0.55-0.56-0.49-0.64
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common----------
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Income statement for another ticker

Before investing one should read a report on Esperion Therapeutics stock analysis. It helps to look at the following income statement items:
  • Topline: A growing topline, as seen from the Esperion Therapeutics revenue chart, as is the case with Esperion Therapeutics indicates a growing business. One needs to compare the QoQ or YoY topline growth of ESPR stock with its peers like FWP stock and FLXN stock to see if the growth compares well with what can be expected for a company in that industry.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-28.96M for Esperion Therapeutics for 2016-Q4. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.
The income statement is also called statement of revenue and expense. The financials along with Esperion Therapeutics historical stock prices provides a lot of details about the firm. .